BR112015016184A2 - derivados de piridona e seu uso no tratamento, melhora ou prevenção de uma doença viral - Google Patents
derivados de piridona e seu uso no tratamento, melhora ou prevenção de uma doença viralInfo
- Publication number
- BR112015016184A2 BR112015016184A2 BR112015016184A BR112015016184A BR112015016184A2 BR 112015016184 A2 BR112015016184 A2 BR 112015016184A2 BR 112015016184 A BR112015016184 A BR 112015016184A BR 112015016184 A BR112015016184 A BR 112015016184A BR 112015016184 A2 BR112015016184 A2 BR 112015016184A2
- Authority
- BR
- Brazil
- Prior art keywords
- viral disease
- amelioration
- prevention
- treatment
- pyridone derivatives
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 230000003612 virological effect Effects 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title abstract 2
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical class OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 title 1
- 229940126523 co-drug Drugs 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical class O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361750023P | 2013-01-08 | 2013-01-08 | |
| PCT/EP2014/050166 WO2014108407A1 (en) | 2013-01-08 | 2014-01-07 | Pyridone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015016184A2 true BR112015016184A2 (pt) | 2017-07-11 |
Family
ID=50070508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015016184A BR112015016184A2 (pt) | 2013-01-08 | 2014-01-07 | derivados de piridona e seu uso no tratamento, melhora ou prevenção de uma doença viral |
Country Status (11)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3290424T1 (sl) | 2015-04-28 | 2023-03-31 | Shionogi & Co., Ltd. | Substituirani policiklični piridonski derivati in njihovo predzdravilo |
| EP3428170B1 (en) | 2015-04-28 | 2021-01-06 | Shionogi & Co., Ltd | Anti-influenza polycyclic pyridone derivative and prodrug thereof |
| CA3008607A1 (en) | 2015-12-15 | 2017-06-22 | Shionogi & Co., Ltd. | A medicament for treating influenza characterized by combining a cap-dependent endonuclease inhibitor and an anti-influenza drug |
| WO2017106820A1 (en) | 2015-12-17 | 2017-06-22 | Thomas Jefferson University | Antiviral agents for drug-resistant influenza a |
| US10889556B2 (en) * | 2016-03-08 | 2021-01-12 | The Regents Of The University Of California | Compositions and methods for inhibiting influenza RNA polymerase PA endonuclease |
| UA125218C2 (uk) | 2016-08-10 | 2022-02-02 | Сіоногі Енд Ко., Лтд. | Фармацевтичні композиції, що містять заміщені поліциклічні піридонові похідні та їх проліки |
| AU2020397059A1 (en) | 2019-12-06 | 2022-07-21 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofurans as modulators of sodium channels |
| CN117794920A (zh) | 2021-06-04 | 2024-03-29 | 沃泰克斯药物股份有限公司 | N-(羟烷基(杂)芳基)四氢呋喃甲酰胺作为钠通道调节剂 |
| EP4511116A1 (en) | 2022-04-22 | 2025-02-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5475109A (en) | 1994-10-17 | 1995-12-12 | Merck & Co., Inc. | Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease |
| CA2554120A1 (en) * | 2004-01-30 | 2005-08-18 | Merck & Co., Inc. | N-benzyl-3,4-dihydroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4-carboxamide compounds useful as hiv integras inhibitors |
| CN101014572B (zh) | 2004-09-15 | 2011-07-06 | 盐野义制药株式会社 | 具有hiv整合酶抑制活性的氨基甲酰基吡啶酮衍生物 |
| TW200716632A (en) | 2005-05-16 | 2007-05-01 | Gilead Sciences Inc | Integrase inhibitor compounds |
| TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
| WO2010110231A1 (ja) | 2009-03-26 | 2010-09-30 | 塩野義製薬株式会社 | 置換された３－ヒドロキシ－４－ピリドン誘導体 |
| WO2011000566A2 (en) | 2009-06-30 | 2011-01-06 | Savira Pharmaceuticals Gmbh | Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections |
-
2014
- 2014-01-07 RU RU2015125570A patent/RU2015125570A/ru not_active Application Discontinuation
- 2014-01-07 JP JP2015551200A patent/JP2016508145A/ja active Pending
- 2014-01-07 MX MX2015008288A patent/MX2015008288A/es unknown
- 2014-01-07 KR KR1020157017812A patent/KR20150103034A/ko not_active Withdrawn
- 2014-01-07 BR BR112015016184A patent/BR112015016184A2/pt not_active IP Right Cessation
- 2014-01-07 CA CA2894452A patent/CA2894452A1/en not_active Abandoned
- 2014-01-07 HK HK15112096.1A patent/HK1211287A1/xx unknown
- 2014-01-07 CN CN201480004181.3A patent/CN104903294A/zh active Pending
- 2014-01-07 HK HK16100551.3A patent/HK1212688A1/zh unknown
- 2014-01-07 WO PCT/EP2014/050166 patent/WO2014108407A1/en not_active Ceased
- 2014-01-07 US US14/149,218 patent/US8952039B2/en not_active Expired - Fee Related
- 2014-01-07 EP EP14703276.7A patent/EP2943469A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| RU2015125570A (ru) | 2017-02-10 |
| US20140194476A1 (en) | 2014-07-10 |
| EP2943469A1 (en) | 2015-11-18 |
| JP2016508145A (ja) | 2016-03-17 |
| HK1212688A1 (zh) | 2016-06-17 |
| CN104903294A (zh) | 2015-09-09 |
| US8952039B2 (en) | 2015-02-10 |
| CA2894452A1 (en) | 2014-07-17 |
| MX2015008288A (es) | 2016-06-02 |
| WO2014108407A1 (en) | 2014-07-17 |
| HK1211287A1 (en) | 2016-05-20 |
| KR20150103034A (ko) | 2015-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015012693A2 (pt) | derivados de pirimidona e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
| BR112015016184A2 (pt) | derivados de piridona e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
| BR112014029016A8 (pt) | derivados de ácido 7-oxo-tiazolopiridina carbônico e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
| BR112014029006A2 (pt) | derivados de 7-oxo-4,7-di-hidro-pirazolo[1,5-a]pirimidina que são úteis no tratamento, melhora ou prevenção de uma doença viral | |
| EA201650029A1 (ru) | Пиразолопиридины и пиразолопиримидины | |
| BR112014008412A2 (pt) | derivados de pirimidin-4-ona e sua utilização no tratamento, na melhora ou na prevenção de uma doença viral | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| BR112015016911A2 (pt) | tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn | |
| EA201690287A1 (ru) | 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом | |
| EA201592256A1 (ru) | Производные имидазопирролидинона и их применение при лечении заболеваний | |
| BR112015021983A8 (pt) | compostos heterocíclicos, composições e usos dos mesmos | |
| EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
| WO2017205536A3 (en) | Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| BR112014001369A2 (pt) | derivados de ácido hidroxâmico de heteroarila e uso dos mesmos no tratamento, melhora ou prevenção de doença viral | |
| EA201590371A1 (ru) | 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний | |
| HK1211289A1 (en) | Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| EA201590453A1 (ru) | Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| EA201592255A1 (ru) | Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания | |
| AR108046A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| EA201691058A1 (ru) | Производные пирролопирролона и их применение для лечения заболеваний | |
| MY207696A (en) | 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof | |
| MX377202B (es) | Derivado basado en 1,2-naftoquinona y metodo de preparacion del mismo. | |
| BR112015004523A2 (pt) | compostos de tetraciclina | |
| EA201692298A1 (ru) | Производные карбоксамидов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law | ||
| B06F | Objections, documents and/or translations needed after an examination request according art. 34 industrial property law | ||
| B06F | Objections, documents and/or translations needed after an examination request according art. 34 industrial property law | ||
| B06I | Technical and formal requirements: publication cancelled |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
| B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2495 DE 30-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |